EichorEICHOR
Location: Jaipur Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Jaipur

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2 · Investigational Site Number : 3560003 · Sanofi · NCT06867094Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · SMS Medical College and Hospital · Walden Biosciences · NCT06466135LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2 · SR Kalla Memorial Gastro & General Hospital · Eli Lilly and Company · NCT07415044A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06006559Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC Wi
Phase 3 · Research Site · AstraZeneca · NCT06357533A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Add
Phase 4 · Bhagwan Mahaveer Cancer Hospital & Research Centre · Bayer · NCT05348876A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
Phase 3 · SMS Medical College & Hospital · Novo Nordisk A/S · NCT05685238A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Livi
Phase 2 · SMS Medical College & Hospital · Novo Nordisk A/S · NCT06717698A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niem
Phase 3 · JK Lone Hospital · Azafaros B.V. · NCT07082725An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Phase 3 · Priyanka Hospital & Cardiac Center · Eli Lilly and Company · NCT07223593A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Phase 3 · Akero Clinical Study Site · Akero Therapeutics, Inc · NCT06528314A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants Wi
Phase 3 · Research Site · AstraZeneca · NCT05211895AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obst
Phase 3 · Asthma Bhawan · Novo Nordisk A/S · NCT07571005Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3 · Research Site · AstraZeneca · NCT06079671A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Phase 4 · Eternal Heart Care Center and Research Institute · Eli Lilly and Company · NCT07438444LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have C
Phase 3 · SR Kalla Memorial Hospital · Boehringer Ingelheim · NCT06632457Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Dee
Phase 3 · Anthos Investigative Site 2306 · Anthos Therapeutics, Inc. · NCT05712200Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease o
Phase 3 · Clinical Trial Site · Alnylam Pharmaceuticals · NCT07181109A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif
Phase 2/Phase 3 · Sawai Man Singh Medical College Hospital (SMS Hospital) · Pfizer · NCT06989437A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurre
Phase 3 · Bhagwan Mahaveer Cancer Hospital & Research Centre · Janssen Research & Development, LLC · NCT07276399A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 · Bhagwan Mahaveer Cancer Hospital & Research Centre · Janssen Research & Development, LLC · NCT07518186A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Phase 2 · Investigational Site Number : 3560009 · Sanofi · NCT06637631A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Phase 3 · Eternal Heart Care Center and Research Institute · Eli Lilly and Company · NCT07392190A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD
Phase 3 · Sawai Man Singh Hospital and Medical College · Hoffmann-La Roche · NCT05878769Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Local Institution - 007-1569 · Mirati Therapeutics Inc. · NCT04613596Empowering Adolescents to Lead Change Using Health Data
NA · WHO · World Health Organization · NCT04963426Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
Phase 1 · Somani Hospital · Aurigene Discovery Technologies Limited · NCT06755450A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vern
Phase 2 · Agrawal Hospital · Laboratoires Thea · NCT07169695Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
NA · Rukmani Birla Hospital · Population Health Research Institute · NCT05701358
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.